+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Tendonitis - Market Insight, Epidemiology and Market Forecast -2032

  • PDF Icon

    Report

  • 141 Pages
  • January 2022
  • Region: Global
  • DelveInsight
  • ID: 5524651
This "Tendonitis- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Tendonitis, historical and forecasted epidemiology as well as the Tendonitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Tendonitis market report provides current treatment practices, emerging drugs, Tendonitis market share of the individual therapies, current and forecasted Tendonitis market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Tendonitis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

Tendonitis Disease Understanding and Treatment Algorithm


The Tendonitis market report gives a thorough understanding of the Tendonitis by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis


This segment of the report covers the detailed diagnostic methods or tests for Tendonitis.

Treatment


It covers the details of conventional and current medical therapies available in the Tendonitis market for the treatment of the condition. It also provides Tendonitis treatment algorithms and guidelines in the United States, Europe, and Japan.

Tendonitis Epidemiology


The Tendonitis epidemiology division provide insights about historical and current Tendonitis patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings


The disease epidemiology covered in the report provides historical as well as forecasted Tendonitis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Tendonitis Epidemiology


The epidemiology segment also provides the Tendonitis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Tendonitis Drug Chapters


Drug chapter segment of the Tendonitis report encloses the detailed analysis of Tendonitis marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Tendonitis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs


The report provides the details of the marketed product available for Tendonitis treatment.

Tendonitis Emerging Drugs


The report provides the details of the emerging therapies under the late and mid-stage of development for Tendonitis treatment.

Tendonitis Market Outlook


The Tendonitis market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Tendonitis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Tendonitis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, Tendonitis market in 7MM is expected to change in the study period 2019-2032.

Key Findings


This section includes a glimpse of the Tendonitis market in 7MM.

The United States Market Outlook


This section provides the total Tendonitis market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook


The total Tendonitis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook


The total Tendonitis market size and market size by therapies in Japan is also mentioned.

Tendonitis Drugs Uptake


This section focusses on the rate of uptake of the potential drugs recently launched in the Tendonitis market or expected to get launched in the market during the study period 2019-2032. The analysis covers Tendonitis market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Tendonitis Pipeline Development Activities


The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Tendonitis key players involved in developing targeted therapeutics.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Tendonitis emerging therapies.

Reimbursement Scenario in Tendonitis


Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL-Views


To keep up with current market trends, we take KOLs and SME's opinion working in Tendonitis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Tendonitis market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis


The publisher performs Competitive and Market Intelligence analysis of the Tendonitis Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Tendonitis, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Tendonitis epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Tendonitis are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Tendonitis market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Tendonitis market

Report Highlights

  • In the coming years, Tendonitis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Tendonitis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Tendonitis. Launch of emerging therapies will significantly impact the Tendonitis market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Tendonitis
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Tendonitis Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Tendonitis Pipeline Analysis
  • Tendonitis Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Tendonitis Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Tendonitis Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Tendonitis Report Assessment


Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions Answered


Market Insights:

  • What was the Tendonitis market share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Tendonitis total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Tendonitis market size during the forecast period (2019-2032)?
  • At what CAGR, the Tendonitis market is expected to grow in 7MM during the forecast period (2019-2032)?
  • What would be the Tendonitis market outlook across the 7MM during the forecast period (2019-2032)?
  • What would be the Tendonitis market growth till 2032, and what will be the resultant market Size in the year 2032?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Tendonitis?
  • What is the historical Tendonitis patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Tendonitis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Tendonitis?
  • Out of all 7MM countries, which country would have the highest prevalent population of Tendonitis during the forecast period (2019-2032)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Tendonitis treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Tendonitis in the USA, Europe, and Japan?
  • What are the Tendonitis marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Tendonitis?
  • How many therapies are developed by each company for Tendonitis treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Tendonitis treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Tendonitis therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Tendonitis and their status?
  • What are the key designations that have been granted for the emerging therapies for Tendonitis?
  • What are the global historical and forecasted market of Tendonitis?

Reasons to Buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Tendonitis market
  • To understand the future market competition in the Tendonitis market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Tendonitis in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Tendonitis market
  • To understand the future market competition in the Tendonitis market

Table of Contents

1 Key Insights2 Report Introduction
3 Tendonitis Market Overview at a Glance
3.1 Market Share (%) Distribution of Tendonitis in 2018
3.2 Market Share (%) Distribution of Tendonitis in 2030
4 Executive Summary of Tendonitis
4.1 Key events
5 Epidemiology and Market Methodology
6 Disease Background and Overview
6.1 Introduction
6.2 Types of Tendonitis
6.2.1 Tennis Elbow (Lateral Epicondylitis)
6.2.2 Golfer’s Elbow (Medial Epicondylitis)
6.2.3 Patellar Tendonitis
6.2.4 Achilles Tendonitis
6.2.5 Supraspinatus Tendonitis
6.2.6 Trigger Finger or Thumb
6.2.7 Tendonitis of the Wrist
6.2.8 Peroneal Tendonitis
6.2.9 Posterior Tibial Tendonitis
6.2.10 Rotator Cutoff Tendonitis
6.3 Stages of Tendonitis
6.4 Signs and Symptoms of Tendonitis
6.5 Causes and Risk Factors of Tendonitis
6.6 Classification
6.7 Pathophysiology
7 Diagnosis of Tendonitis
7.1 Differential Diagnosis
7.2 Diagnosis Guidelines
7.2.1 American Academy of Family Physicians (AAFP)
7.3 Ohio State University and Wexner Medical Center Jointly Released Recommendations for the Management of Tendinopathy
8 Preventions
9 Treatment
9.1 Treatment Guidelines
9.1.1 Recommendations for the Treatment of Tendinopathy
10 Epidemiology and Patient Population
10.1 Key Findings
10.2 Epidemiology of Tendonitis
10.3 Epidemiology Scenario
10.3.1 Total Incident Cases of Tendonitis
10.3.2 Total Gender-specific Cases of Tendonitis
10.3.3 Total Region-specific Cases of Tendonitis
10.3.4 Total Treated Cases of Tendonitis
11 Patient Journey12 Key Endpoints in Tendonitis Clinical Trials
13 Marketed Therapies
13.1 Ostenil Tendon: TRB Chemedica
13.1.1 Product Description
13.1.2 Regulatory Milestones
13.1.3 Other Developmental Activities
13.1.4 Safety and Efficacy
13.1.5 Clinical Development
13.2 VergenixSTR: CollPlant
13.2.1 Product Description
13.2.2 Regulatory Milestones
13.2.3 Other Developmental Activities
13.2.4 Pivotal Clinical Trial
14 Emerging Therapies
14.1 AmnioFix (Micronized DHACM): MiMedx Group
14.1.1 Product Description
14.1.2 Other Development Activities
14.1.3 Clinical Development
14.2 Platelet-rich Plasma (PRP): University of Wisconsin-Madison/GE Electric Healthcare
14.2.1 Product Description
14.2.2 Other Development Activities
14.2.3 Clinical Development
14.3 Joyclu (Diclofenac Etalhyaluronate/SI-613): Seikagaku Corporation/Ono Pharmaceutical
14.3.1 Product Description
14.3.2 Other Development Activities
14.3.3 Clinical Development
14.4 Cosentyx (Secukinumab/AIN457): Novartis
14.4.1 Product Description
14.4.2 Other Development Activities
14.4.3 Clinical Development
14.4.4 Safety and Efficacy
14.5 Amniotic Fluid Tissue: R3 Stem Cell
14.5.1 Product Description
14.5.2 Clinical Development
14.6 Platelet-rich Plasma (PRP): University of Wisconsin-Madison/ DePuy Synthes
14.6.1 Product Description
14.6.2 Clinical Development
14.7 Ortho-ATI: Orthocell
14.7.1 Product Description
14.7.2 Other Development Activities
14.7.3 Clinical Development
14.7.4 Safety and Efficacy
14.8 Adipose-Derived Regenerative Cells: InGeneron
14.8.1 Product Description
14.8.2 Other Development Activities
14.8.3 Clinical Development
14.8.4 Safety and Efficacy
15 Tendonitis: 7 Major Market Analysis
15.1 Key Findings
15.2 Market Outlook
15.3 Market Size of Tendonitis
15.3.1 Total Market Size of Tendonitis
15.3.2 Market Size of Tendonitis by Therapies
16 KOL Views17 Market Drivers18 Market Barriers19 SWOT Analysis20 Unmet Needs
21 Appendix
21.1 Bibliography
21.2 Report Methodology
22 Capabilities23 Disclaimer24 About the Publisher
List of Tables
Table 1: Summary of Tendonitis, Market, Epidemiology, and Key Events (2018-2030)
Table 2: Histopathological Classification of Tendon Disorders
Table 3: Recommendations for Managing Tendinopathy
Table 4: Key Recommendations for Practice
Table 5: Recommendations for the Treatment of Tendinopathy
Table 6: Pain Reduction and Load Management
Table 7: Isotonic Loading Progression
Table 8: Energy Storage Loading Progression (Plyometric)
Table 9: Return to Sport/Activity
Table 10: Total Incident Cases of Tendonitis (in Millions) in the 7MM (2018-2030)
Table 11: Total Gender-specific Cases of Tendonitis (in Millions) in the 7MM (2018-2030)
Table 12: Total Region-specific Cases of Tendonitis (in Millions) in the 7MM (2018-2030)
Table 13: Total Treated Cases of Tendonitis (in Millions) in the 7MM (2018-2030)
Table 14: Ostenil Tendon, Clinical Trial Description, 2021
Table 15: AmnioFix (Micronized DHACM), Clinical Trial Description, 2021
Table 16: Platelet-rich Plasma (PRP), Clinical Trial Description, 2021
Table 17: SI-613, Clinical Trial Description, 2021
Table 18: Cosentyx (Secukinumab/AIN457), Clinical Trial Description, 2021
Table 19: Amniotic Fluid Tissue, Clinical Trial Description, 2021
Table 20: Platelet-rich Plasma (PRP), Clinical Trial Description, 2021
Table 21: Ortho-ATI, Clinical Trial Description, 2021
Table 22: Adipose-derived Regenerative Cells, Clinical Trial Description, 2021
Table 23: 7MM Market Size of Tendonitis in USD Million (2018-2030)
Table 24: 7MM Market Size of Tendonitis by Therapies in USD Million (2018-2030)
List of Figures
Figure 1: Epidemiology and Market Methodology
Figure 2: Understanding of Tendonitis
Figure 3: Types of Tendonitis
Figure 4: Tennis Elbow (Lateral Epicondylitis)
Figure 5: Golfer’s Elbow (Medial Epicondylitis)
Figure 6: Patellar Tendonitis
Figure 7: Achilles Tendonitis
Figure 8: Supraspinatus Tendonitis
Figure 9: Trigger finger or thumb
Figure 10: Tendonitis of the Wrist
Figure 11: Peroneal Tendonitis
Figure 12: Posterior Tibial Tendonitis
Figure 13: Rotator Cutoff Tendonitis
Figure 14: Sign and Symptoms of Tendonitis
Figure 15: Causes and Risk factors of Tendonitis
Figure 16: Classification of Tendinopathy
Figure 17: Comparison of Tendonitis and Tendinosis
Figure 18: RICE Treatment of Tendonitis
Figure 19: Total Incident Cases of Tendonitis in the 7MM (2018-2030)
Figure 20: Total Gender-specific Cases of Tendonitis in the 7MM (2018-2030)
Figure 21: Total Region-specific Cases of Tendonitis in the 7MM (2018-2030)
Figure 22: Total Treated Cases of Tendonitis in the 7MM (2018-2030)
Figure 23: Market Size of Tendonitis in the 7MM, USD Million (2018-2030)
Figure 24: 7MM Market Size of Tendonitis by Therapies in USD Million (2018-2030)

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • TRB Chemedica
  • CollPlant
  • MiMedx Group
  • University of Wisconsin-Madison/GE Electric Healthcare
  • Seikagaku Corporation/Ono Pharmaceutical
  • Novartis
  • R3 Stem Cell
  • University of Wisconsin-Madison/ DePuy Synthes
  • Orthocell
  • InGeneron